Review



full length human btk  (Carna Inc)


Bioz Verified Symbol Carna Inc is a verified supplier
Bioz Manufacturer Symbol Carna Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    Carna Inc full length human btk
    Full Length Human Btk, supplied by Carna Inc, used in various techniques. Bioz Stars score: 95/100, based on 65 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/full length human btk/product/Carna Inc
    Average 95 stars, based on 65 article reviews
    full length human btk - by Bioz Stars, 2026-02
    95/100 stars

    Images



    Similar Products

    full length human btk  (Carna Inc)
    95
    Carna Inc full length human btk
    Full Length Human Btk, supplied by Carna Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/full length human btk/product/Carna Inc
    Average 95 stars, based on 1 article reviews
    full length human btk - by Bioz Stars, 2026-02
    95/100 stars
    		  Buy from Supplier
    btk (c481s, human, full-length recombinant, mw: 77 kda)  (Promega)
    90
    Promega btk (c481s, human, full-length recombinant, mw: 77 kda)
    A IHC staining of <t>BTK</t> expression on OSCC tissues in CCRT-resistant (upper) and treatment-naïve tissue, normal tonsil as a control (bottom). Black arrow indicates the immune cells. B Q-score of BTK expression in TSGH patients with OSCC with treatment-naïve ( n = 52) and CCRT-resistant tissues ( n = 18). C Kaplan–Meier curves showing the effect of low- and high-BTK expression on the overall survival of TSGH patients with OSCC. D Overall survival of TSGH patients with OSCC relapses from CCRT. Median gene expression was used to determine low/high cut-off value. E Graphical representation of BTK expression in OSCC patients’ samples with or without additional RT/chemotherapy (top image: BTK expression in patient tissue, bottom image: BTK mRNA expression in patient tissue; rBTK: <t>BTK</t> <t>recombinant</t> protein standard, 77 kDa). F Kaplan–Meier curves showing the effect of low- and high-BTK expression on the overall survival of TCGA patients with OSCC ( n = 269). G Overall survival of TCGA patients with OSCC without additional therapy. H Overall survival of TCGA patients with OSCC relapses from CCRT. Median gene expression was used to determine low/high cut-off value. * p < 0.05, ** p < 0.01.
    Btk (C481s, Human, Full Length Recombinant, Mw: 77 Kda), supplied by Promega, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/btk (c481s, human, full-length recombinant, mw: 77 kda)/product/Promega
    Average 90 stars, based on 1 article reviews
    btk (c481s, human, full-length recombinant, mw: 77 kda) - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    standard btk (c481s, human, full-length recombinant, mw: 77 kda)  (Promega)
    90
    Promega standard btk (c481s, human, full-length recombinant, mw: 77 kda)
    A IHC staining of <t>BTK</t> expression on OSCC tissues in CCRT-resistant (upper) and treatment-naïve tissue, normal tonsil as a control (bottom). Black arrow indicates the immune cells. B Q-score of BTK expression in TSGH patients with OSCC with treatment-naïve ( n = 52) and CCRT-resistant tissues ( n = 18). C Kaplan–Meier curves showing the effect of low- and high-BTK expression on the overall survival of TSGH patients with OSCC. D Overall survival of TSGH patients with OSCC relapses from CCRT. Median gene expression was used to determine low/high cut-off value. E Graphical representation of BTK expression in OSCC patients’ samples with or without additional RT/chemotherapy (top image: BTK expression in patient tissue, bottom image: BTK mRNA expression in patient tissue; rBTK: <t>BTK</t> <t>recombinant</t> protein standard, 77 kDa). F Kaplan–Meier curves showing the effect of low- and high-BTK expression on the overall survival of TCGA patients with OSCC ( n = 269). G Overall survival of TCGA patients with OSCC without additional therapy. H Overall survival of TCGA patients with OSCC relapses from CCRT. Median gene expression was used to determine low/high cut-off value. * p < 0.05, ** p < 0.01.
    Standard Btk (C481s, Human, Full Length Recombinant, Mw: 77 Kda), supplied by Promega, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/standard btk (c481s, human, full-length recombinant, mw: 77 kda)/product/Promega
    Average 90 stars, based on 1 article reviews
    standard btk (c481s, human, full-length recombinant, mw: 77 kda) - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    recombinant full-length human btk kinase v2941  (Promega)
    90
    Promega recombinant full-length human btk kinase v2941
    A IHC staining of <t>BTK</t> expression on OSCC tissues in CCRT-resistant (upper) and treatment-naïve tissue, normal tonsil as a control (bottom). Black arrow indicates the immune cells. B Q-score of BTK expression in TSGH patients with OSCC with treatment-naïve ( n = 52) and CCRT-resistant tissues ( n = 18). C Kaplan–Meier curves showing the effect of low- and high-BTK expression on the overall survival of TSGH patients with OSCC. D Overall survival of TSGH patients with OSCC relapses from CCRT. Median gene expression was used to determine low/high cut-off value. E Graphical representation of BTK expression in OSCC patients’ samples with or without additional RT/chemotherapy (top image: BTK expression in patient tissue, bottom image: BTK mRNA expression in patient tissue; rBTK: <t>BTK</t> <t>recombinant</t> protein standard, 77 kDa). F Kaplan–Meier curves showing the effect of low- and high-BTK expression on the overall survival of TCGA patients with OSCC ( n = 269). G Overall survival of TCGA patients with OSCC without additional therapy. H Overall survival of TCGA patients with OSCC relapses from CCRT. Median gene expression was used to determine low/high cut-off value. * p < 0.05, ** p < 0.01.
    Recombinant Full Length Human Btk Kinase V2941, supplied by Promega, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant full-length human btk kinase v2941/product/Promega
    Average 90 stars, based on 1 article reviews
    recombinant full-length human btk kinase v2941 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    A IHC staining of BTK expression on OSCC tissues in CCRT-resistant (upper) and treatment-naïve tissue, normal tonsil as a control (bottom). Black arrow indicates the immune cells. B Q-score of BTK expression in TSGH patients with OSCC with treatment-naïve ( n = 52) and CCRT-resistant tissues ( n = 18). C Kaplan–Meier curves showing the effect of low- and high-BTK expression on the overall survival of TSGH patients with OSCC. D Overall survival of TSGH patients with OSCC relapses from CCRT. Median gene expression was used to determine low/high cut-off value. E Graphical representation of BTK expression in OSCC patients’ samples with or without additional RT/chemotherapy (top image: BTK expression in patient tissue, bottom image: BTK mRNA expression in patient tissue; rBTK: BTK recombinant protein standard, 77 kDa). F Kaplan–Meier curves showing the effect of low- and high-BTK expression on the overall survival of TCGA patients with OSCC ( n = 269). G Overall survival of TCGA patients with OSCC without additional therapy. H Overall survival of TCGA patients with OSCC relapses from CCRT. Median gene expression was used to determine low/high cut-off value. * p < 0.05, ** p < 0.01.

    Journal: Oncogenesis

    Article Title: Inhibition of Bruton’s tyrosine kinase as a therapeutic strategy for chemoresistant oral squamous cell carcinoma and potential suppression of cancer stemness

    doi: 10.1038/s41389-021-00308-z

    Figure Lengend Snippet: A IHC staining of BTK expression on OSCC tissues in CCRT-resistant (upper) and treatment-naïve tissue, normal tonsil as a control (bottom). Black arrow indicates the immune cells. B Q-score of BTK expression in TSGH patients with OSCC with treatment-naïve ( n = 52) and CCRT-resistant tissues ( n = 18). C Kaplan–Meier curves showing the effect of low- and high-BTK expression on the overall survival of TSGH patients with OSCC. D Overall survival of TSGH patients with OSCC relapses from CCRT. Median gene expression was used to determine low/high cut-off value. E Graphical representation of BTK expression in OSCC patients’ samples with or without additional RT/chemotherapy (top image: BTK expression in patient tissue, bottom image: BTK mRNA expression in patient tissue; rBTK: BTK recombinant protein standard, 77 kDa). F Kaplan–Meier curves showing the effect of low- and high-BTK expression on the overall survival of TCGA patients with OSCC ( n = 269). G Overall survival of TCGA patients with OSCC without additional therapy. H Overall survival of TCGA patients with OSCC relapses from CCRT. Median gene expression was used to determine low/high cut-off value. * p < 0.05, ** p < 0.01.

    Article Snippet: The purified standard BTK (C481S, Human, full-length recombinant, MW: 77 kDa, Promega, Wisconsin, USA) as loading control.

    Techniques: Immunohistochemistry, Expressing, Control, Gene Expression, Recombinant